Stay updated on LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.

Latest updates to the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page
- Check2 days agoChange DetectedA new revision entry (v3.6.4) was added to the study record history, replacing the previous (v3.6.3); this reflects an update to the history tracking on the ClinicalTrials.gov page.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe study history page shows a new revision label (v3.6.3) replacing the previous v3.6.2, indicating a small refresh to the page's revision history rather than a change to the study information.SummaryDifference0.1%

- Check31 days agoChange DetectedThe Study Record History now includes a new revision entry (v3.6.2) and removes the previous revision (v3.6.0), indicating an update to the page rendering or underlying system.SummaryDifference0.1%

- Check45 days agoChange DetectedThe history shows the study now indicates no longer looking for participants, signaling that enrollment has closed. The record version has been updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.3%

- Check52 days agoChange DetectedThe record history now shows a new revision from v3.5.4 to v3.5.5, indicating a page update to the ClinicalTrials.gov interface for this study record. This update reflects an underlying system or display change rather than a content change to the study.SummaryDifference0.1%

- Check74 days agoChange DetectedThe Record History now shows Revision: v3.5.4, replacing the prior v3.5.3. This reflects an updated edition of the page's record-keeping view.SummaryDifference0.1%

Stay in the know with updates to LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818 and MEK162 With Third Agent in BRAF Melanoma Clinical Trial page.